Form 4: Alkermes Director Christopher Wright Granted Equity Awards Valued at Over $600,000

Alkermes plc Director Christopher I. Wright was granted non-qualified stock options and restricted stock units on May 21, 2025, as part of his compensation, aligning his interests with shareholders.

Summary

• On May 21, 2025, Christopher I. Wright, a Director of Alkermes plc (ALKS), received new equity awards.
• The awards include 13,474 non-qualified stock options with an exercise price of $30.53 per share, which will vest in full on May 21, 2026, and expire on May 21, 2035.
• Additionally, Mr. Wright was granted 6,142 Restricted Stock Units (RSUs), with each RSU representing a contingent right to receive one ordinary share.
• The RSU award will also vest in full on May 21, 2026.

Sentiment

Score: 6

Explanation: The document reports a routine equity grant to a director, which is a positive for aligning management interests with shareholders, but does not contain information that would significantly alter the company's financial outlook or operations.

Positives

• The granting of equity awards to a director aligns their financial interests with those of the company's shareholders, encouraging long-term value creation.
• These awards are a standard component of director compensation, indicating a continued commitment to attracting and retaining experienced board members.

Future Outlook

The future outlook indicates that Christopher I. Wright's equity awards will vest on May 21, 2026, at which point he will gain full ownership rights to the shares underlying the options and RSUs, subject to the terms of the awards.

Industry Context

The granting of equity compensation to directors is a common practice within the pharmaceutical and biotechnology industries, serving as a key mechanism to align the interests of board members with the long-term performance of the company and its shareholders. This practice is consistent with broader trends in corporate governance aimed at fostering accountability and incentivizing value creation.

Comparison to Industry Standards

• Equity-based compensation, including stock options and restricted stock units, is a common practice across the pharmaceutical and biotechnology industries for attracting and retaining qualified directors and executives.
• While specific grant sizes vary based on company size, performance, and individual roles, the structure of these awards is consistent with industry benchmarks for director compensation.

Stakeholder Impact

• Shareholders: The equity awards align the director's interests with shareholders, potentially leading to better long-term decision-making focused on shareholder value.

Next Steps

• The shares subject to the stock option and restricted stock unit awards are scheduled to vest on May 21, 2026.

Key Dates

Keywords

Alkermes, ALKS, Form 4, Insider Transaction, Equity Award, Stock Option, Restricted Stock Unit, Director Compensation, Corporate Governance